Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

Open in Screener

VIR

Vir Biotechnology Inc

Jan 30 • 04:00PM ET

10.31

Dollar change -0.59
Percentage change -5.41	%

Healthcare • Biotechnology • USA • NASD

Peers: REGN MRNA LLY PFE JNJ GILD BNTX AZN SNY NVAX

| Held by: IJR IWM VTI VB XBI VBK IJS VXF SPSM IWN

Index	RUT	P/E	-	EPS (ttm)	-3.92	Insider Own	36.31%	Shs Outstand	136.71M	Perf Week	-7.95%
Market Cap	1.42B	Forward P/E	-	EPS next Y	-3.54	Insider Trans	-0.06%	Shs Float	87.71M	Perf Month	38.11%
Income	-533.34M	PEG	-	EPS next Q	-0.87	Inst Own	49.37%	Short Float	8.96%	Perf Quarter	33.03%
Sales	78.62M	P/S	18.06	EPS this Y	15.42%	Inst Trans	-1.40%	Short Ratio	3.53	Perf Half Y	1.68%
Book/sh	9.08	P/B	1.14	EPS next Y	8.81%	ROA	-30.10%	Short Interest	7.86M	Perf Year	8.30%
Cash/sh	7.29	P/C	1.41	EPS next 5Y	9.14%	ROE	-36.58%	52W Range	6.56 - 14.45	Perf YTD	40.46%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-34.12%	ROI	-39.98%	52W High	-28.65%	Beta	0.64
Dividend TTM	-	Quick Ratio	8.94	Sales past 5Y	532.77%	Gross Margin	78.24%	52W Low	57.16%	ATR (14)	0.85
Dividend Ex-Date	Nov 03, 2010	Current Ratio	8.94	EPS Y/Y TTM	12.57%	Oper. Margin	-688.05%	RSI (14)	55.38	Volatility	7.49% 8.32%
Employees	587	Debt/Eq	0.09	Sales Y/Y TTM	-33.82%	Profit Margin	-678.40%	Recom	1.56	Target Price	31.38
Option/Short	Yes / Yes	LT Debt/Eq	0.08	EPS Q/Q	-28.52%	Payout	-	Rel Volume	0.80	Prev Close	10.90
Sales Surprise	-57.04%	EPS Surprise	-48.22%	Sales Q/Q	-9.81%	Earnings	Oct 31 AMC	Avg Volume	2.23M	Price	10.31
SMA20	3.72%	SMA50	20.53%	SMA200	17.05%	Trades		Volume	1,784,971	Change	-5.41%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-29-24	Downgrade	JP Morgan	Overweight → Neutral	$23 → $9
Sep-08-23	Downgrade	BofA Securities	Buy → Neutral	$23 → $14
Mar-06-23	Upgrade	JP Morgan	Neutral → Overweight	$35 → $34
Feb-21-23	Upgrade	Goldman	Neutral → Buy	$41 → $53
Jan-27-23	Upgrade	Morgan Stanley	Underweight → Equal-Weight	$18 → $30
Sep-14-22	Initiated	SVB Leerink	Outperform	$40
Sep-09-22	Initiated	Morgan Stanley	Underweight	$15
Mar-03-22	Upgrade	Robert W. Baird	Underperform → Neutral	$36 → $28
Dec-21-21	Downgrade	Robert W. Baird	Neutral → Underperform	$36
Oct-25-21	Upgrade	JP Morgan	Underweight → Neutral	$29 → $37
Sep-22-21	Downgrade	Goldman	Buy → Neutral	$64 → $62
Jun-04-21	Resumed	Robert W. Baird	Neutral	$45
Jan-27-21	Downgrade	JP Morgan	Neutral → Underweight	$30
Jan-20-21	Reiterated	H.C. Wainwright	Buy	$100 → $125
Oct-05-20	Initiated	BofA Securities	Buy	$55
Sep-14-20	Upgrade	Goldman	Neutral → Buy	$48 → $54
Sep-11-20	Upgrade	JP Morgan	Underweight → Neutral	$29
Aug-20-20	Initiated	Needham	Buy	$62
Mar-19-20	Downgrade	JP Morgan	Neutral → Underweight	$26
Mar-13-20	Downgrade	Goldman	Buy → Neutral

Show Previous Ratings

Jan-23-25 06:35PM	Why Vir Biotechnology, Inc. (VIR) Is Skyrocketing Now (Insider Monkey) +6.36% -5.09%
Jan-10-25 02:32PM	Morgan Stanley Doubles Vir Biotechnology Price Forecast - Here's Why (Benzinga)
Jan-09-25 08:30AM	Morgan Stanley upgrades Vir Biotechnology to 'overweight,' raises PT to $20 (Investing.com)
08:18AM	Vir Biotechnology Reports Promising Trial Results for Cancer Therapies (TipRanks)
Jan-08-25 04:06PM	Vir Biotechnology Catapults 58% On Promising Results In Cancer Treatment (Investor's Business Daily) +58.17%
07:45AM	Loading…
07:45AM	Vir Biotechnology Announces Encouraging Safety and Efficacy Data in Ongoing Dose Escalation Trials for Dual Masked T-Cell Engagers VIR-5818 in Solid Tumors and VIR-5500 in mCRPC (Business Wire)
07:25AM	Vir Biotechnology price target lowered to $14 from $15 at BofA (TipRanks)
Dec-18-24 09:30AM	Vir Biotechnology to Present at the 43rd Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-12-24 04:05PM	Vir Biotechnology Receives FDA Breakthrough Therapy Designation and EMA PRIME Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta (Business Wire)
Dec-03-24 04:07PM	Janux Catapults 49% On 'Unprecedented' Results In Prostate Cancer; Vir Goes For A Ride (Investor's Business Daily) +12.88% -8.97%
09:02AM	Janux, Vir Catapult On 'Unprecedented' Results In Prostate Cancer Patients (Investor's Business Daily)
Nov-26-24 09:30AM	Vir Biotechnology to Host Virtual Investor Event on PRO-XTEN Masked T-Cell Engager Programs (Business Wire)
Nov-25-24 09:30AM	Vir Biotechnology to Participate in the 7th Annual Evercore ISI HealthCONx Conference (Business Wire)
Nov-18-24 09:15PM	Vir Biotechnology Presents Positive Chronic Hepatitis Delta Clinical Trial Data and Announces Initiation of Phase 3 Registrational Program (Business Wire) -12.23%
04:05PM	Vir Biotechnology Receives Positive Opinion on Orphan Drug Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta from European Medicines Agency (Business Wire)
01:39PM	Loading…
Nov-15-24 01:39PM	What's Going On With Liver Disease Focused Vir Biotechnology Stock Is Friday? (Benzinga) -7.29%
11:00AM	Vir Biotechnology Announces Positive End-of-Treatment Results for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B from the MARCH Study at AASLD The Liver Meeting (Business Wire)
Nov-01-24 05:01PM	Vir Biotechnology Inc (VIR) Q3 2024 Earnings Call Highlights: Strategic Restructuring and ... (GuruFocus.com) +23.63%
12:04AM	U.S. Drugmakers Are Breaking Up With Their Chinese Supply-Chain Partners (The Wall Street Journal)
Oct-31-24 05:20PM	Vir Biotechnology, Inc. (VIR) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
04:05PM	Vir Biotechnology Reports Third Quarter 2024 Financial Results and Provides Corporate Update (Business Wire)
Oct-18-24 03:04PM	State Street Corp's Strategic Acquisition in Vir Biotechnology Inc (GuruFocus.com)
Oct-17-24 04:30PM	Vir Biotechnology to Provide Business Update and Report Third Quarter 2024 Financial Results on October 31, 2024 (Business Wire)
Oct-15-24 08:16AM	Vir Biotechnology Announces Clinical Advances Across Hepatitis Delta and Hepatitis B Programs at AASLDs The Liver Meeting 2024 (Business Wire)
Oct-03-24 04:00PM	Vir Biotechnology to Participate in the H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference (Business Wire) +5.59%
Sep-10-24 08:05AM	Vir Biotechnology Appoints Jason OByrne as Chief Financial Officer (Business Wire)
Sep-09-24 04:05PM	Vir Biotechnology Announces Closing of Exclusive Worldwide License Agreement With Sanofi for Multiple Potential Best-in-Class Clinical-Stage T-Cell Engagers (Business Wire)
Sep-04-24 08:30AM	Global Coronavirus Therapeutics Market Size Projected to Exceed $16 Billion By the End of 2031 (GlobeNewswire)
Aug-22-24 08:05AM	Vir Biotechnology to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference (Business Wire)
Aug-06-24 09:55AM	Wall Street Analysts See a 258.38% Upside in Vir Biotechnology (VIR): Can the Stock Really Move This High? (Zacks)
05:50PM	Loading…
Aug-01-24 05:50PM	Vir Biotechnology, Inc. (VIR) Reports Q2 Loss, Lags Revenue Estimates (Zacks) -5.34%
04:02PM	Vir Biotechnology Reports Second Quarter 2024 Financial Results and Announces Strategic Restructuring to Prioritize Clinical-Stage Pipeline Opportunities (Business Wire)
04:01PM	Vir Biotechnology Acts on Expanded Strategy of Powering the Immune System Through Exclusive Worldwide License Agreement with Sanofi for Multiple Potential Best-in-Class Clinical-Stage T-cell Engagers (Business Wire)
Jul-18-24 04:05PM	Vir Biotechnology to Report Second Quarter 2024 Financial Results on August 1, 2024 (Business Wire)
Jul-04-24 10:01AM	3 Undervalued Biotech Gems With 200%+ Analyst Price Targets (InvestorPlace)
Jun-26-24 08:05AM	Vir Biotechnology Receives FDA IND Clearance and Fast Track Designation for Tobevibart and Elebsiran for the Treatment of Chronic Hepatitis Delta Infection (Business Wire)
Jun-06-24 01:26PM	Vir Biotechnology (VIR) Up on Positive Data From HDV Study (Zacks) -5.37%
Jun-05-24 02:51PM	Why Is Infectious Disease-Focused Vir Biotechnology Stock Trading Higher On Wednesday? (Benzinga) +19.66%
05:30AM	Tobevibart Monotherapy and Combination Therapy with Elebsiran Achieved High Virologic Response and ALT Normalization in People Living with the Hepatitis Delta Virus After 12 and 24 Weeks of Treatment (Business Wire)
May-29-24 04:05PM	Vir Biotechnology to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference (Business Wire) -5.87%
08:05AM	Vir Biotechnology Appoints Mark Eisner, M.D., M.P.H. as Chief Medical Officer (Business Wire)
May-23-24 04:05PM	Vir Biotechnology to Host 2024 Annual Meeting of Stockholders (Business Wire) -6.33%
May-22-24 08:05AM	Multiple Abstracts Highlighting Vir Biotechnologys Latest Hepatitis Delta & B Data Accepted for Presentation at the EASL Congress 2024 (Business Wire) +11.36%
May-21-24 08:17AM	Vir Biotechnology Announces SOLSTICE Data to be Featured as an Oral Presentation at the European Association for the Study of the Liver (EASL) Congress 2024 (Business Wire) +5.37%
May-13-24 07:21PM	Brii Biosciences Announces Two Breakthrough Therapy Designations for BRII-877 and BRII-835 Building on Extensive Clinical Evidence from Multiple Phase 2 Studies (PR Newswire)
May-09-24 10:46AM	Cytokinetics, Incorporated (NASDAQ:CYTK) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-07-24 09:55AM	Wall Street Analysts Think Vir Biotechnology (VIR) Could Surge 188.65%: Read This Before Placing a Bet (Zacks)
May-03-24 01:05PM	Vir Biotechnology, Inc. (NASDAQ:VIR) Q1 2024 Earnings Call Transcript (Insider Monkey) +13.18%
06:05AM	Q1 2024 Vir Biotechnology Inc Earnings Call (Thomson Reuters StreetEvents)
04:06AM	Vir Biotechnology Inc (VIR) (Q1 2024) Earnings Call Transcript Highlights: Navigating ... (GuruFocus.com)
May-02-24 09:56PM	VIR Stock Earnings: Vir Biotechnology Beats EPS for Q1 2024 (InvestorPlace) +5.03%
06:05PM	Vir Biotechnology, Inc. (VIR) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Vir Biotechnology Provides Corporate Update and Reports First Quarter 2024 Financial Results (Business Wire)
Apr-30-24 04:05PM	Vir Biotechnology to Participate in the BofA Securities Healthcare Conference 2024 (Business Wire)
Apr-24-24 12:00PM	What Makes Vir Biotechnology (VIR) a New Buy Stock (Zacks)
Apr-18-24 08:00AM	Vir Biotechnology Announces Nomination of Norbert Bischofberger, Ph.D. and Ramy Farid, Ph.D. to its Board of Directors (Business Wire)
Apr-11-24 04:30PM	Vir Biotechnology to Provide Business Update and Report First Quarter 2024 Financial Results on May 2, 2024 (Business Wire)
Apr-04-24 07:01PM	Vir Biotechnology Inc CEO Backer De Sells 72,995 Shares (GuruFocus.com)
Mar-22-24 07:00AM	Brii Biosciences Provides Corporate Update and Reports Full-Year 2023 Financial Results (PR Newswire)
Mar-19-24 02:58PM	From Six Figures to Seven: 3 Biotech Stocks Set to Make Millionaires (InvestorPlace) -6.37%
Mar-13-24 11:07AM	Billionaires Biotech Bets: 3 Stocks Dominating Bill Gates Portfolio (InvestorPlace)
Mar-05-24 08:05AM	Vir Biotechnology Completes Enrollment of Phase 2 Chronic Hepatitis Delta SOLSTICE Trial Ahead of Schedule (Business Wire)
Feb-23-24 01:54PM	Q4 2023 Vir Biotechnology Inc Earnings Call (Thomson Reuters StreetEvents) +11.94%
10:34AM	Vir Biotechnology, Inc. (NASDAQ:VIR) Q4 2023 Earnings Call Transcript (Insider Monkey)
09:55AM	Wall Street Analysts Believe Vir Biotechnology, Inc. (VIR) Could Rally 186.41%: Here's is How to Trade (Zacks)
08:05AM	Vir Biotechnology to Participate in Upcoming Investor Healthcare Conferences (Business Wire)
Feb-22-24 05:50PM	Vir Biotechnology, Inc. (VIR) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results (Business Wire)
Feb-20-24 04:30PM	Vir Biotechnology Announces Dr. Phil Pang Will Step Down as Chief Medical Officer (Business Wire)
Feb-14-24 03:45PM	3 Hidden-Gem Biotech Stocks Ready to Ride a Massive Market Wave (InvestorPlace) +10.62%
Feb-01-24 04:05PM	Vir Biotechnology to Provide Business Update and Report Fourth Quarter 2023 Financial Results on February 22, 2024 (Business Wire)
Jan-15-24 11:32AM	Vir Biotechnology (VIR) Gains 21.7% in 3 Months: Here's Why (Zacks)
Dec-17-23 07:00AM	I See a Vir-y Good Trade (TheStreet.com)
07:00AM	I See a Good Trade on a $10 Biotech Stock (TheStreet.com)
Dec-13-23 04:05PM	Vir Biotechnology Announces Strategic Steps to Reduce Operating Expenses and Focus Investment on Areas with Highest Potential for Value Creation (Business Wire) +9.11%
Dec-06-23 04:05PM	Vir Biotechnology to Present at J.P. Morgan 2024 42nd Annual Healthcare Conference (Business Wire)
Nov-30-23 06:10AM	7 Small-Cap Stocks to Buy BEFORE the Year-End Rally (InvestorPlace)
Nov-13-23 08:00AM	Vir Biotechnology to Present New Data from Its Ongoing Phase 2 Chronic Hepatitis Delta and B Trials Today at AASLDs The Liver Meeting 2023 (Business Wire)
Nov-10-23 08:00AM	Vir Biotechnology to Present Late-Breaking Data from Its Ongoing Phase 2 Chronic Hepatitis B and Delta Trials at AASLDs The Liver Meeting 2023 (Business Wire) +7.99%
Nov-08-23 08:05AM	Vir Biotechnology Ranked the Fastest-Growing Company in North America on the 2023 Deloitte Technology Fast 500 (Business Wire)
Nov-04-23 11:42AM	Vir Biotechnology, Inc. (NASDAQ:VIR) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-03-23 09:02AM	Q3 2023 Vir Biotechnology Inc Earnings Call (Thomson Reuters StreetEvents) +6.96%
Nov-02-23 07:00PM	Vir Biotechnology Inc (VIR) Reports Q3 2023 Financial Results (GuruFocus.com) +5.13%
04:05PM	Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2023 Financial Results (Business Wire)
Oct-30-23 08:00AM	Vir Biotechnology Appoints Jennifer Towne, Ph.D., as Executive Vice President and Chief Scientific Officer (Business Wire)
Oct-23-23 02:50AM	7 Biotech Stocks to Get In Now Before Investors Catch On (InvestorPlace)
Oct-12-23 04:05PM	Vir Biotechnology to Participate in the H.C. Wainwright 4th Annual Hepatitis B Virus (HBV) Conference (GlobeNewswire) -5.98%
Oct-11-23 08:00AM	Vir Biotechnology Announces Multiple Abstracts Highlighting New Chronic Hepatitis B and Hepatitis Delta Data Accepted for Presentation at AASLD's The Liver Meeting 2023 (GlobeNewswire)
Oct-05-23 04:30PM	Vir Biotechnology to Provide Business Update and Report Third Quarter 2023 Financial Results on November 2, 2023 (GlobeNewswire)
Oct-03-23 07:59AM	Vir Biotechnology Awarded BARDA Funding to Support Development of Antibody Platform Technologies for Global Infectious Disease Threats (GlobeNewswire)
Sep-20-23 08:00AM	Vir Biotechnology Announces First Participant Dosed in New Phase 1 Trial Evaluating VIR-1388, an Investigational T Cell Vaccine for the Prevention of HIV (GlobeNewswire)
Sep-19-23 05:07AM	Down More Than 50%: 2 Strong Buy Stocks That Are Too Cheap to Ignore (TipRanks)
Sep-08-23 09:34AM	Adobe upgraded, DigitalOcean double downgraded: Wall Street's top analyst calls (The Fly)
Aug-29-23 04:30PM	Vir Biotechnology to Participate in Upcoming Investor Healthcare Conferences (GlobeNewswire)
Aug-12-23 11:05AM	10 Oversold Healthcare Stocks to Buy (Insider Monkey)
Aug-11-23 10:15AM	Is Vir Biotechnology Stock a Buy? (Motley Fool)
Aug-07-23 06:03AM	Analysts Just Made A Major Revision To Their Vir Biotechnology, Inc. (NASDAQ:VIR) Revenue Forecasts (Simply Wall St.)
Aug-04-23 01:40PM	Vir Biotechnology, Inc. (NASDAQ:VIR) Q2 2023 Earnings Call Transcript (Insider Monkey)
Aug-03-23 06:05PM	Vir Biotechnology, Inc. (VIR) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
04:05PM	Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2023 Financial Results (GlobeNewswire)

Vir Biotechnology, Inc. operates as a clinical-stage immunology company that focuses on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The firm's technology platforms include antibody, T cell, innate immunity and siRNA, which are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. The company was founded by Robert Taylor Nelsen, Klaus Frueh, Jay Parrish, Lawrence Corey, and Louis Picker in April 7, 2016 and is headquartered in San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
SATO VICKI L	Director	Jan 08 '25	Sale	12.52	10,960	137,219	1,312,391	Jan 08 08:03 PM
VICKI LEE SATO	Director	Jan 08 '25	Proposed Sale	7.89	43,840	345,898		Jan 08 04:22 PM
de Verneuil Vanina	EVP and General Counsel	Dec 02 '24	Sale	8.22	76	625	56,973	Dec 04 03:35 PM
VANINA ALEXANDRA HUARD DE VERN	Officer	Dec 02 '24	Proposed Sale	8.22	76	625		Dec 02 05:08 PM
de Verneuil Vanina	EVP and General Counsel	Nov 06 '24	Sale	10.11	4,397	44,454	56,973	Nov 07 07:20 PM
VANINA DE VERNEUIL	Officer	Nov 06 '24	Proposed Sale	9.64	4,397	42,387		Nov 06 04:55 PM
de Verneuil Vanina	EVP and General Counsel	Nov 05 '24	Sale	9.47	2,347	22,225	61,370	Nov 05 05:51 PM
de Verneuil Vanina	EVP and General Counsel	Nov 01 '24	Sale	7.20	1,403	10,107	63,717	Nov 05 05:51 PM
VANINA DE VERNEUIL	Officer	Nov 05 '24	Proposed Sale	9.37	2,347	21,991		Nov 05 04:23 PM
Napolitano Janet	Director	Sep 09 '24	Sale	7.80	12,190	95,032	11,616	Sep 10 04:28 PM
JANET ANN NAPOLITANO	Director	Sep 09 '24	Proposed Sale	7.76	12,190	94,594		Sep 09 04:29 PM
Ramasastry Saira	Director	Jun 11 '24	Sale	10.95	4,000	43,789	14,619	Jun 12 12:21 PM
De Backer Marianne	Chief Executive Officer	Apr 03 '24	Sale	9.46	72,995	690,365	678,457	Apr 04 04:14 PM
HANLY ANN M.	EVP & Chief Technology Officer	Apr 01 '24	Sale	10.05	2,711	27,251	132,069	Apr 02 08:58 PM
Lee Sung	EVP & Chief Financial Officer	Mar 27 '24	Sale	9.89	6,008	59,404	100,492	Mar 28 12:18 PM
HANLY ANN M.	EVP & Chief Technology Officer	Feb 22 '24	Sale	10.05	12,296	123,521	134,780	Feb 26 07:34 PM
Pang Phillip	EVP & Chief Medical Officer	Feb 22 '24	Sale	10.05	14,568	146,344	250,111	Feb 26 07:31 PM
SCANGOS GEORGE A	Director	Feb 26 '24	Sale	11.65	17,722	206,522	112,989	Feb 26 07:30 PM
SCANGOS GEORGE A	Director	Feb 22 '24	Sale	10.05	10,028	100,737	130,711	Feb 26 07:30 PM
SCANGOS GEORGE A	Director	Feb 20 '24	Sale	10.22	16,872	172,385	140,739	Feb 20 09:02 PM
SCANGOS GEORGE A	Director	Feb 16 '24	Sale	10.24	10,878	111,386	157,611	Feb 20 09:02 PM
Pang Phillip	EVP & Chief Medical Officer	Feb 16 '24	Sale	10.24	3,321	34,006	264,679	Feb 16 06:56 PM

Open in Screener

DNLI

Denali Therapeutics Inc

Jan 30 • 04:00PM ET

23.58

Dollar change +0.17
Percentage change 0.73	%

Healthcare • Biotechnology • USA • NASD

DNLI Denali Therapeutics Inc daily Stock Chart

Peers: BIIB REGN ALNY UTHR IONS MRNA SRPT NBIX VRTX PTCT

| Held by: IWM VTI VB VXF XBI VBK IBB IWO SCHA VTWO

Index	RUT	P/E	-	EPS (ttm)	-2.76	Insider Own	13.43%	Shs Outstand	143.84M	Perf Week	1.29%
Market Cap	3.39B	Forward P/E	-	EPS next Y	-3.02	Insider Trans	-1.36%	Shs Float	124.59M	Perf Month	14.41%
Income	-427.49M	PEG	-	EPS next Q	-0.82	Inst Own	88.55%	Short Float	6.40%	Perf Quarter	-15.12%
Sales	0.00M	P/S	-	EPS this Y	-162.11%	Inst Trans	6.37%	Short Ratio	8.47	Perf Half Y	-2.60%
Book/sh	9.17	P/B	2.57	EPS next Y	-8.83%	ROA	-31.77%	Short Interest	7.97M	Perf Year	34.59%
Cash/sh	5.81	P/C	4.06	EPS next 5Y	-	ROE	-35.09%	52W Range	14.56 - 33.33	Perf YTD	15.70%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-21.99%	ROI	-31.36%	52W High	-29.25%	Beta	1.43
Dividend TTM	-	Quick Ratio	9.98	Sales past 5Y	350.08%	Gross Margin	-	52W Low	61.95%	ATR (14)	1.21
Dividend Ex-Date	-	Current Ratio	9.98	EPS Y/Y TTM	-197.15%	Oper. Margin	-	RSI (14)	57.43	Volatility	4.50% 5.95%
Employees	445	Debt/Eq	0.04	Sales Y/Y TTM	-100.00%	Profit Margin	-	Recom	1.18	Target Price	40.00
Option/Short	Yes / Yes	LT Debt/Eq	0.03	EPS Q/Q	12.36%	Payout	-	Rel Volume	0.85	Prev Close	23.41
Sales Surprise	-100.00%	EPS Surprise	-5.86%	Sales Q/Q	-100.00%	Earnings	Nov 06 AMC	Avg Volume	940.63K	Price	23.58
SMA20	8.97%	SMA50	3.88%	SMA200	1.32%	Trades		Volume	803,360	Change	0.73%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-07-25	Initiated	Robert W. Baird	Outperform	$31
Jan-03-25	Initiated	William Blair	Outperform
Dec-16-24	Upgrade	Stifel	Hold → Buy	$37
Oct-10-24	Resumed	Raymond James	Mkt Perform
Oct-07-24	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Dec-13-23	Initiated	Citigroup	Buy	$32
Nov-20-23	Resumed	JP Morgan	Overweight	$28
Oct-24-23	Resumed	Cantor Fitzgerald	Overweight	$85 → $35
Sep-06-23	Initiated	B. Riley Securities	Buy	$38
Jan-30-23	Initiated	SVB Securities	Outperform	$50
Dec-05-22	Initiated	Cowen	Outperform
Nov-02-22	Upgrade	BTIG Research	Neutral → Buy	$38
Nov-02-22	Initiated	BofA Securities	Buy	$40
Jun-23-22	Initiated	Berenberg	Buy	$39
Dec-10-21	Resumed	Raymond James	Mkt Perform
Sep-21-21	Initiated	Oppenheimer	Outperform	$85
Sep-01-21	Initiated	SMBC Nikko	Outperform	$78
May-18-21	Initiated	UBS	Buy	$70
Feb-26-21	Reiterated	H.C. Wainwright	Buy	$80 → $95
Feb-10-21	Upgrade	Cantor Fitzgerald	Neutral → Overweight	$105

Show Previous Ratings

Today 08:00AM	Denali Therapeutics Announces Upcoming Presentations on Hunter Syndrome (MPS II) and TransportVehicle Enabled Investigational Therapeutic Tividenofusp Alfa at the 2025 WORLDSymposium (GlobeNewswire)
Jan-17-25 11:18AM	Why Denali Therapeutics (DNLI) Is the Biotech Stock with Biggest Upside Potential (Insider Monkey)
Jan-13-25 08:00AM	Denali Therapeutics Announces Key Anticipated 2025 Milestones and Priorities to Further Advance Its Therapeutics Portfolio for Neurodegeneration and Lysosomal Storage Diseases (GlobeNewswire)
Jan-08-25 08:00AM	Denali Therapeutics Announces U.S. FDA Breakthrough Therapy Designation Granted to Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II) (GlobeNewswire)
07:25AM	Denali Therapeutics price target lowered to $32 from $35 at BTIG (TipRanks)
04:33PM	Loading…
Jan-07-25 04:33PM	These Stocks Moved the Most Today: Nvidia, Micron, Aurora Innovation, Tesla, Carvana, Moderna, Palantir, and More (Barrons.com) +6.86%
04:08PM	Denali Reverses Its Fortunes With 'Too Early' Miss In ALS Treatment (Investor's Business Daily)
02:16PM	These Stocks Are Moving the Most Today: Nvidia, Micron, Aurora Innovation, Tesla, Carvana, Moderna, Palantir, and More (Barrons.com)
12:48PM	Denali Therapeutics' Amyotrophic Lateral Sclerosis Misses Pivotal Trial, But Analyst Says It Was Expected (Benzinga)
10:13AM	Denali Therapeutics Phase II/III trial of ALS therapy fails to meet primary endpoint (Clinical Trials Arena)
10:13AM	Denali Therapeutics ALS therapy fails to meet primary endpoint in Phase II/III trial (Clinical Trials Arena)
09:33AM	Denali Therapeutics Ratchets Up Losses On Misstep In ALS Treatment. Why The Game Isn't Over Yet. (Investor's Business Daily)
04:41AM	ALS drugs from Denali, Calico come up short, marking setback for Healey trial (BioPharma Dive)
Jan-06-25 04:30PM	Denali Therapeutics Announces Topline Results for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform Trial (GlobeNewswire) -6.77%
Jan-03-25 01:08PM	Denali Therapeutics Neurodegenerative Disease Platform Sparks Analyst Optimistic (Benzinga)
06:25AM	Loading…
Dec-17-24 06:25AM	Denali Therapeutics upgraded to Buy from Hold at Stifel (TipRanks)
Dec-06-24 11:31AM	Why Is Denali Therapeutics (DNLI) Down 21.2% Since Last Earnings Report? (Zacks) +6.73%
Dec-05-24 08:00AM	Denali Therapeutics Announces First Participant Dosed in Phase 2a Study of LRRK2 Inhibitor, BIIB122, in LRRK2-Associated Parkinson's Disease (GlobeNewswire)
Nov-06-24 04:01PM	Denali Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights (GlobeNewswire) +6.87%
Oct-29-24 10:01AM	Denali Therapeutics Inc. (DNLI) May Report Negative Earnings: Know the Trend Ahead of Q3 Release (Zacks)
Oct-13-24 04:56PM	Denali Therapeutics Inc. (DNLI): Jeff Bezos Is Buying This Stock Now (Insider Monkey)
Sep-16-24 11:22AM	Strength Seen in Denali Therapeutics (DNLI): Can Its 10.1% Jump Turn into More Strength? (Zacks)
Sep-04-24 08:15AM	High-dose Spinraza meets study goal; Top Dyne executives exit (BioPharma Dive)
Sep-03-24 08:00AM	Denali Therapeutics Announces Successful Meeting with the FDA and Plans to File for Accelerated Approval of Tividenofusp Alfa (DNL310) for the Treatment of MPS II (Hunter Syndrome) (GlobeNewswire)
Aug-19-24 10:13AM	Genetic testing in Parkinsons disease patients: a standard of care imperative? (Medical Device Network)
Aug-14-24 02:00PM	Denali Therapeutics Announces Publication in Science Translational Medicine Demonstrating the Potential of the Oligonucleotide Transport Vehicle Platform to Achieve Broad Biodistribution of Antisense Oligonucleotides in the CNS and Muscle Following Intravenous Administration (GlobeNewswire)
Aug-06-24 09:55AM	Wall Street Analysts Believe Denali Therapeutics (DNLI) Could Rally 79.62%: Here's is How to Trade (Zacks)
Aug-01-24 06:45AM	Denali Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights (GlobeNewswire)
Jul-23-24 06:13AM	Denali Therapeutics (DNLI) Stock Jumps 9.7%: Will It Continue to Soar? (Zacks)
Jul-16-24 03:19PM	Denali Therapeutics Stock Gets Technical Rating Upgrade (Investor's Business Daily)
07:09PM	Loading…
Jul-08-24 07:09PM	3 Longevity Stocks to Buy for Anti-Aging Breakthroughs (InvestorPlace)
Jun-28-24 08:37AM	Denali (DNLI) Outperforms Industry in 3 Months: Here's Why (Zacks)
Jun-24-24 09:07AM	Denali Therapeutics (DNLI) Moves 5.8% Higher: Will This Strength Last? (Zacks)
Jun-12-24 07:00AM	Flagship Pioneering and ProFound Therapeutics Announce Agreement to Identify Novel First-in-Class Therapeutics for the Treatment of Obesity under Strategic Partnership with Pfizer (PR Newswire)
Jun-06-24 11:31AM	Why Is Denali Therapeutics (DNLI) Up 15.6% Since Last Earnings Report? (Zacks)
Jun-04-24 01:17PM	Denali's (DNLI) Candidate Selected for FDA's START Pilot Program (Zacks)
Jun-03-24 08:00AM	Denali Therapeutics Announces FDA Has Selected DNL126 (ETV:SGSH) for MPS IIIA (Sanfilippo Syndrome Type A) for START Pilot Program Intended to Accelerate Development of Rare Disease Therapies (GlobeNewswire) +9.81%
May-09-24 07:00AM	Flagship Pioneering and Metaphore Biotechnologies Announce Research Collaboration with Novo Nordisk to Develop Next-Generation Therapeutics for Obesity Management (PR Newswire)
May-08-24 11:17AM	Stifel Adjusts Price Target on Denali Therapeutics to $22 From $26, Maintains Hold Rating (MT Newswires) +12.17%
09:16AM	Wedbush Adjusts Denali Therapeutics' Price Target to $30 From $31, Keeps Outperform Rating (MT Newswires)
08:20AM	Denali (DNLI) Q1 Earnings Miss, Pipeline Progress in Focus (Zacks)
May-07-24 10:56PM	DNLI Stock Earnings: Denali Therapeutics Beats EPS for Q1 2024 (InvestorPlace)
05:56PM	Denali Therapeutics Q1 2024 Earnings: Misses Revenue Estimates Amid Strategic Shifts (GuruFocus.com)
04:01PM	Denali Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights (GlobeNewswire)
May-01-24 08:00AM	Denali Therapeutics Announces Completion of Enrollment for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform Trial (GlobeNewswire)
Apr-09-24 08:46AM	Why Denali Therapeutics (DNLI) Stock Might be a Great Pick (Zacks)
Apr-08-24 08:00AM	Flagship Appoints Amy O'Shea as CEO-Partner and Chief Executive Officer of Invaio Sciences (PR Newswire)
Mar-28-24 11:30AM	Why Is Denali Therapeutics (DNLI) Up 2.8% Since Last Earnings Report? (Zacks)
Mar-19-24 08:30AM	Flagship Pioneering Named to Fast Company's Annual List of the World's Most Innovative Companies of 2024 (PR Newswire)
Feb-28-24 08:08AM	Denali's (DNLI) Q4 Earnings Miss, Pipeline in Focus, Stock Up (Zacks) -13.45%
Feb-27-24 08:31AM	Denali Therapeutics Inc (DNLI) Reports Full Year and Q4 2023 Financial Results (GuruFocus.com) +38.25%
08:05AM	Denali Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights (GlobeNewswire)
08:00AM	Denali Therapeutics Announces $500 million Private Placement Equity Financing (GlobeNewswire)
06:53AM	Denali, fresh off study setback, gets $500M lift (BioPharma Dive)
Feb-16-24 08:39AM	UPDATE 2-Denali-Sanofi's ALS drug fails to meet mid-stage trial goal (Reuters) -7.30%
08:22AM	Denali-Sanofi's ALS drug fails to meet main goal of mid-stage trial (Reuters)
07:13AM	ALS drug from Denali, Sanofi falls short in mid-stage study (BioPharma Dive)
Feb-07-24 08:00AM	Denali Therapeutics Announces New Data and Expansion of Its Blood-Brain Barrier (BBB)-Crossing Enzyme Replacement Therapy Programs at WORLDSymposium (GlobeNewswire)
Feb-01-24 08:00AM	Denali Therapeutics Announces Presentations on Its Investigational Blood-Brain Barrier (BBB)-Crossing Enzyme Replacement Therapies at the Upcoming 2024 WORLDSymposium (GlobeNewswire)
Jan-31-24 11:04PM	Baillie Gifford Reduces Stake in Denali Therapeutics Inc (GuruFocus.com)
Jan-26-24 10:00AM	Denali's (DNLI) Pipeline Progresses Despite Stiff Competition (Zacks)
Jan-11-24 01:11PM	40 Cities with the Lowest Life Expectancy in the US (Insider Monkey)
Jan-09-24 08:44AM	DEAN BANKS APPOINTED CEO OF INDIGO AG AND CEO-PARTNER OF FLAGSHIP PIONEERING (PR Newswire)
Jan-08-24 08:00AM	Denali Therapeutics Announces Key Anticipated 2024 Milestones and Priorities to Further Advance Its Therapeutics Portfolio for Neurodegeneration and Lysosomal Storage Diseases (GlobeNewswire) +5.27%
06:30AM	Flagship Pioneering Debuts Enabling Technologies Initiative (PR Newswire)
06:30AM	Flagship Pioneering and Samsung Announce Collaboration to Advance Groundbreaking Technologies in Translational Science and Medicine (PR Newswire)
Jan-02-24 01:57PM	3 Biotech Stocks at the Forefront of the Quest for Eternal Youth (InvestorPlace)
Dec-22-23 06:22AM	40 Cities with the Highest Life Expectancy in the US (Insider Monkey)
Dec-21-23 09:55AM	Does Denali Therapeutics Inc. (DNLI) Have the Potential to Rally 123.38% as Wall Street Analysts Expect? (Zacks)
Dec-07-23 11:31AM	Why Is Denali Therapeutics Inc. (DNLI) Down 5.2% Since Last Earnings Report? (Zacks)
Nov-27-23 07:01PM	Flagship Pioneering Marks Official Opening of UK Hub with Event Convening Life Science Leaders (PR Newswire)
09:55AM	Wall Street Analysts See a 163.82% Upside in Denali Therapeutics Inc. (DNLI): Can the Stock Really Move This High? (Zacks)
Nov-21-23 06:00AM	Flagship Pioneering Unveils Quotient Therapeutics to Create Transformative Medicines Informed by a New Frontier of Genetics (PR Newswire) -5.11%
Nov-07-23 05:50PM	Denali Therapeutics Inc. (DNLI) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
04:01PM	Denali Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights (GlobeNewswire)
Nov-06-23 09:55AM	Wall Street Analysts Think Denali Therapeutics Inc. (DNLI) Could Surge 121.53%: Read This Before Placing a Bet (Zacks)
Nov-01-23 10:30AM	Flagship Pioneering Launches Pioneering Intelligence (PR Newswire)
Oct-19-23 10:30AM	Flagship Pioneering Announces the Merger of Two Leading Programmable Medicine Platforms to Form Sail Biomedicines (PR Newswire)
Oct-06-23 04:41AM	Orchard Therapeutics PLC Sponsored ADR (ORTX) Surges 96.0%: Is This an Indication of Further Gains? (Zacks)
Oct-02-23 07:00AM	Flagship Pioneering Appoints John Lepore as CEO-Partner and CEO of ProFound Therapeutics (PR Newswire)
Sep-27-23 08:31AM	Flagship Pioneering Named to Fortune's 2023 'Change the World' List (PR Newswire)
Sep-11-23 06:30AM	Flagship Pioneering Announces Appointment of Amanda Kay as Chief Business Development Officer (PR Newswire)
Sep-09-23 03:59PM	10 Biotech Stocks with Biggest Upside (Insider Monkey)
Sep-07-23 11:30AM	Why Is Denali Therapeutics Inc. (DNLI) Down 0.1% Since Last Earnings Report? (Zacks)
Aug-30-23 08:30AM	Denali Therapeutics Announces New Interim Data from Phase 1/2 Study of DNL310 (ETV:IDS) in MPS II (Hunter Syndrome) at SSIEM 2023 (GlobeNewswire)
Aug-29-23 09:00AM	Invaio achieves first registration for citrus greening solution featuring Trecise technology (PR Newswire)
Aug-11-23 11:36AM	20 Countries that Have the Most Billionaires Per Capita (Insider Monkey)
Aug-10-23 12:02PM	Denali (DNLI) Q2 Earnings Beat on Higher Collaboration Revenues (Zacks)
06:03AM	Pinning Down Denali Therapeutics Inc.'s (NASDAQ:DNLI) P/S Is Difficult Right Now (Simply Wall St.)
Aug-08-23 06:05PM	Denali Therapeutics Inc. (DNLI) Tops Q2 Earnings and Revenue Estimates (Zacks)
04:01PM	Denali Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights (GlobeNewswire)
Jun-29-23 05:13AM	Cash In on the Longevity Boom: 3 Biotech Stocks to Buy Now (InvestorPlace)
Jun-27-23 02:23PM	In the wake of Denali Therapeutics Inc.'s (NASDAQ:DNLI) latest US$402m market cap drop, institutional owners may be forced to take severe actions (Simply Wall St.)
Jun-26-23 10:00AM	Salt Lake City Ups the Ante in Bid to Become a Fintech Hub (The Wall Street Journal)
Jun-21-23 03:21PM	Denali (DNLI) Provides Update on Hunter Syndrome Study (Zacks)
06:00AM	Flagship Pioneering Unveils Empress Therapeutics to Revolutionize Drug Discovery by Applying the Power of Genetics to Identify Small Molecule Drugs (PR Newswire)
Jun-20-23 04:20PM	Denali Says Hunter Syndrome Candidate Lowers Disease-Associated Biomarker (Benzinga)
07:00AM	Denali Therapeutics Announces Robust Reduction in Neurofilament Light (NfL) with DNL310 (ETV:IDS) Treatment in MPS II (Hunter Syndrome) (GlobeNewswire)
Jun-09-23 11:30AM	Why Is Amicus Therapeutics (FOLD) Up 8.1% Since Last Earnings Report? (Zacks)
Jun-08-23 11:30AM	Why Is Exelixis (EXEL) Down 0.6% Since Last Earnings Report? (Zacks)

Denali Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. Its product pipeline includes LRRK2, RIPK1, TREM2, and Tau. The company was founded by Ryan J. Watts, Marc Tessier-Lavigne, and Alexander Schuth on October 14, 2013 and is headquartered in San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Ho Carole	Chief Medical Officer	Jan 06 '25	Sale	20.22	12,255	247,796	178,580	Jan 08 08:26 PM
Ho Carole	Chief Medical Officer	Jan 07 '25	Sale	20.81	2,907	60,495	175,673	Jan 08 08:26 PM
Schuth Alexander O.	COFO and Secretary	Jan 06 '25	Sale	20.22	12,255	247,796	247,215	Jan 08 08:25 PM
Schuth Alexander O.	COFO and Secretary	Jan 07 '25	Sale	20.81	2,907	60,495	244,308	Jan 08 08:25 PM
Watts Ryan J.	President and CEO	Jan 06 '25	Sale	20.22	29,266	591,759	260,721	Jan 08 08:24 PM
Watts Ryan J.	President and CEO	Jan 07 '25	Sale	20.81	7,650	159,196	253,071	Jan 08 08:24 PM
Krognes Steve E.	Director	Jan 07 '25	Sale	20.81	3,339	69,485	25,757	Jan 08 08:23 PM
Ho Carole	Officer	Jan 07 '25	Proposed Sale	20.81	2,907	60,495		Jan 07 08:14 PM
Schuth Alexander O.	Officer	Jan 07 '25	Proposed Sale	20.81	2,907	60,495		Jan 07 08:12 PM
Watts Ryan J.	Director	Jan 07 '25	Proposed Sale	20.81	7,650	159,196		Jan 07 08:10 PM
Krognes Steve E.	Director	Jan 07 '25	Proposed Sale	20.81	3,339	69,485		Jan 07 08:08 PM
Schuth Alexander O.	Officer	Jan 06 '25	Proposed Sale	20.22	12,255	247,781		Jan 07 08:06 PM
Watts Ryan J.	Director	Jan 06 '25	Proposed Sale	20.22	29,266	591,723		Jan 07 08:03 PM
Ho Carole	Officer	Jan 06 '25	Proposed Sale	20.22	12,255	247,786		Jan 07 08:01 PM
SATO VICKI L	Director	Jan 02 '25	Sale	20.91	3,080	64,403	107,976	Jan 03 04:13 PM
VICKI LEE SATO	Director	Jan 02 '25	Proposed Sale	20.38	6,160	125,541		Jan 02 04:23 PM
Schuth Alexander O.	COFO and Secretary	Dec 27 '24	Option Exercise	5.28	6,708	35,418	205,290	Dec 31 04:18 PM
STEVE KROGNES	Director	Dec 31 '24	Proposed Sale	20.24	30,000	607,200		Dec 31 04:17 PM
Ho Carole	Chief Medical Officer	Nov 25 '24	Option Exercise	0.68	17,845	12,135	136,655	Nov 27 04:44 PM
Schuth Alexander O.	COFO and Secretary	Nov 22 '24	Option Exercise	0.68	20,516	13,951	198,582	Nov 26 05:19 PM
Schenkein David P	Director	Nov 11 '24	Option Exercise	18.00	47,165	848,970	68,661	Nov 13 04:18 PM
Schenkein David P	Director	Nov 11 '24	Sale	32.51	59,441	1,932,665	9,220	Nov 13 04:18 PM
Schuth Alexander O.	COFO and Secretary	Nov 07 '24	Option Exercise	5.28	15,558	82,146	193,624	Nov 12 04:44 PM
Schuth Alexander O.	COFO and Secretary	Nov 07 '24	Sale	29.91	15,558	465,286	178,066	Nov 12 04:44 PM
SATO VICKI L	Director	Nov 07 '24	Sale	30.00	1,020	30,600	111,056	Nov 12 04:43 PM
DAVID SCHENKEIN	Director	Nov 11 '24	Proposed Sale	31.35	59,441	1,863,475		Nov 12 07:47 AM
ALEXANDER SCHUTH	Officer	Nov 07 '24	Proposed Sale	29.55	15,558	459,739		Nov 07 04:39 PM
SATO VICKI L	Director	Nov 01 '24	Sale	27.07	3,080	83,376	112,076	Nov 05 04:21 PM
Watts Ryan J.	President and CEO	Oct 18 '24	Option Exercise	0.68	40,000	27,200	275,807	Oct 22 04:30 PM
Watts Ryan J.	President and CEO	Oct 18 '24	Sale	27.69	40,000	1,107,600	235,807	Oct 22 04:30 PM
RYAN WATTS	Director	Oct 18 '24	Proposed Sale	27.42	40,000	1,096,800		Oct 18 04:19 PM
Krognes Steve E.	Director	Sep 30 '24	Sale	29.03	30,000	870,900	29,096	Oct 02 04:37 PM
STEVE KROGNES	Director	Sep 30 '24	Proposed Sale	29.43	30,000	882,900		Sep 30 04:25 PM
SATO VICKI L	Director	Sep 13 '24	Sale	30.00	1,020	30,600	115,156	Sep 16 04:17 PM
VICKI LEE SATO	Director	Sep 13 '24	Proposed Sale	27.96	6,160	172,234		Sep 13 04:25 PM
SATO VICKI L	Director	Sep 03 '24	Sale	25.00	3,080	77,007	116,176	Sep 04 06:26 PM
Watts Ryan J.	President and CEO	Aug 20 '24	Sale	23.79	2,260	53,765	235,807	Aug 22 04:16 PM
Krognes Steve E.	Director	Aug 20 '24	Sale	23.79	1,727	41,085	32,677	Aug 22 04:15 PM
Schuth Alexander O.	COFO and Secretary	Aug 20 '24	Sale	23.65	5,806	137,286	180,613	Aug 22 04:14 PM
Schuth Alexander O.	COFO and Secretary	Aug 21 '24	Sale	24.78	2,547	63,115	178,066	Aug 22 04:14 PM
Ho Carole	Chief Medical Officer	Aug 21 '24	Sale	24.57	20,005	491,571	118,810	Aug 22 04:14 PM
Ho Carole	Chief Medical Officer	Aug 20 '24	Sale	23.79	2,453	58,357	138,815	Aug 22 04:14 PM
CAROLE HO	Officer	Aug 21 '24	Proposed Sale	23.65	20,005	473,118		Aug 21 04:42 PM
ALEXANDER SCHUTH	Officer	Aug 21 '24	Proposed Sale	23.65	2,547	60,237		Aug 21 04:40 PM
Krognes Steve E.	Director	Aug 20 '24	Proposed Sale	23.79	1,727	41,085		Aug 20 08:09 PM
Schuth Alexander O.	Officer	Aug 20 '24	Proposed Sale	23.79	2,453	58,357		Aug 20 08:09 PM
Watts Ryan J.	Director	Aug 20 '24	Proposed Sale	23.79	2,260	53,765		Aug 20 08:08 PM
Ho Carole	Officer	Aug 20 '24	Proposed Sale	23.79	2,453	58,356		Aug 20 08:08 PM
ALEXANDER SCHUTH	Officer	Aug 20 '24	Proposed Sale	23.95	3,353	80,304		Aug 20 04:27 PM
Schuth Alexander O.	COFO and Secretary	Aug 13 '24	Sale	22.89	2,272	52,006	186,419	Aug 15 04:10 PM
Ho Carole	Chief Medical Officer	Aug 13 '24	Sale	22.89	2,337	53,494	141,268	Aug 15 04:09 PM
Schuth Alexander O.	Officer	Aug 13 '24	Proposed Sale	22.89	2,272	52,006		Aug 13 08:37 PM
Ho Carole	Officer	Aug 13 '24	Proposed Sale	22.89	2,337	53,494		Aug 13 08:36 PM
Krognes Steve E.	Director	Jul 01 '24	Sale	22.12	30,000	663,668	34,404	Jul 03 09:13 PM
Krognes Steve E.	Director	Jun 13 '24	Sale	21.79	688	14,992	52,620	Jul 03 09:13 PM
SATO VICKI L	Director	Jul 01 '24	Sale	22.14	3,080	68,204	119,256	Jul 03 09:13 PM
Cook Jennifer E.	Director	Jun 06 '24	Sale	21.73	1,458	31,682	20,038	Jun 10 08:06 PM
SATO VICKI L	Director	May 15 '24	Sale	20.39	1,674	34,133	116,369	May 17 04:28 PM
SATO VICKI L	Director	Apr 15 '24	Sale	18.29	1,666	30,471	118,043	Apr 17 05:14 PM
Krognes Steve E.	Director	Apr 01 '24	Sale	20.50	92,500	1,896,250	47,341	Apr 02 06:07 PM
SATO VICKI L	Director	Mar 15 '24	Sale	20.10	1,666	33,487	119,709	Mar 19 04:27 PM
SATO VICKI L	Director	Feb 15 '24	Sale	18.37	1,666	30,604	121,375	Feb 20 05:38 PM
Krognes Steve E.	Director	Feb 13 '24	Sale	17.29	2,750	47,548	139,841	Feb 15 09:16 PM
Watts Ryan J.	President and CEO	Feb 13 '24	Sale	17.29	9,589	165,794	238,067	Feb 15 09:15 PM
Ho Carole	Chief Medical Officer	Feb 13 '24	Sale	17.29	2,784	48,135	145,010	Feb 15 09:14 PM
Ho Carole	Chief Medical Officer	Feb 14 '24	Sale	17.79	1,405	24,995	143,605	Feb 15 09:14 PM
Schuth Alexander O.	COFO and Secretary	Feb 14 '24	Sale	17.66	20,128	355,460	187,341	Feb 15 09:14 PM
Schuth Alexander O.	COFO and Secretary	Feb 13 '24	Sale	17.29	2,716	46,960	207,469	Feb 15 09:14 PM
Schuth Alexander O.	COFO and Secretary	Feb 08 '24	Option Exercise	0.68	50,000	34,000	210,185	Feb 12 04:48 PM

VIR

Vir Biotechnology Inc

DNLI

Denali Therapeutics Inc

Upgrade your FINVIZ experience